Practical clinical use of laser photodynamic therapy in the treatment of bladder carcinoma in situ
- 28 Downloads
Studies have shown that haematoporphyrin derivative (HPD) concentrates preferentially in dysplastic and neoplastic tissue, and that illumination of HPD-sensitized carcinoma with 632-nm wavelength light causes tumour destruction. We have treated 14 patients with bladder carcinoma in this way, who fit a rigid protocol, with follow-up ranging from 3–26 months. Eleven have shown no recurrence and two were considered partial responders who each showed recurrence at one year and were re-treated successfully. One patient had multiple tumours initially and responded to the point where he could be managed conventionally. One patient was lost to follow-up. Rigid patient selection and limited bladder distension reduce morbidity to transient irritative symptoms and to photosensitivity. Early clinical results have shown photodynamic therapy to be a safe and promising technique for the management of non-invasive bladder cancer in patients who are refractory to standard surgical and chemotherapeutic regimens.
Key wordsBladder carcinoma Dihaematoporphyrin ether Endocystoscopy Bladder biopsy Urine cytology
Unable to display preview. Download preview PDF.
- 2.Figge FHJ, Weiland GS, Mangiello LOJ. Cancer detection and therapy. Affinity of neoplastic, embryonic, and traumatized tissues for porphyrins and metalloporphyrins.Proc Soc Exp Biol Med 1948,68:640–1Google Scholar
- 4.Hisazumi H, Miyoshi N, Naito K, Misaki T. Whole bladder wall photoradiation therapy for carcinoma in situ of the bladder: A preliminary report.J Urol 1983,131:884Google Scholar
- 8.Kelly JF, Snell ME, Berenbaum MC. Photodynamic destruction of human bladder carcinoma.Br J Cancer 1975,31:237–44Google Scholar
- 10.Lipson RL, Pratt AH, Baldes EJ, Dockerty MB. Hematoporphyrin derivative for detection of cervical cancer.Am J Obstet Gynecol 1964,24:178–84Google Scholar